Adimab LLC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Adimab LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011812
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Adimab LLC (Adimab) is an antibody discovery technology provider that offers antibody discovery and optimization platform. The company discovers antibodies for a range of disease areas including oncology, immunomodulation, neuroscience and pain, inflammation, cardiovascular and metabolic disease, and infectious disease. Its platform delivers and optimizes various panels of therapeutically relevant antibodies that meet the standards for affinity, epitope coverage, species cross reactivity and developability. The company has completed discovery programs in various protein classes such as serum proteins, TNF superfamily receptors, ECM adhesion receptors, enzymes, natural peptides, cytokines, ion channels and GPCRs. Adimab is headquartered in Lebanon, New Hampshire, the US.

Adimab LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Adimab LLC, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Adimab Raises US$13.8 Million In Series F Financing 13
Partnerships 15
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16
iTeos Therapeutics Enters into Agreement with Adimab 17
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18
Adimab Enters into Research Agreement with Kite Pharma 19
Adimab Enters into Discovery Agreement with Celgene 20
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21
Adimab Enters into Agreement with Acceleron Pharma 22
Adimab Enters into Agreement with Oncothyreon 23
Adimab Enters into Agreement with Surface Oncology 24
Adimab Enters into Agreement with Potenza Therapeutics 25
Five Prime Therapeutics Enters Into Research Agreement With Adimab 26
Jounce Therapeutics Enters Into Research Agreement With Adimab 27
Alector Enters Into Research Agreement With Adimab 28
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29
Adimab Expands Agreement with Innovent Biologics 30
GlaxoSmithKline Expands its Partnership with Adimab 31
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33
Adimab Enters Into Co-Development Agreement With Gilead Sciences 34
Adimab Enters Into Co-Development Agreement With Biogen Idec 35
Adimab Enters Into Co-Development Agreement With Novo Nordisk 36
Arsanis Enters into Agreement with Adimab 37
Licensing Agreements 38
Eli Lilly Enters into Licensing Agreement with Adimab 38
Arsanis Enters into Licensing Agreement with Adimab 39
Kite Pharma Exercises Option for Licensing Agreement with Adimab 40
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 41
Adimab Enters into Licensing Agreement with Merck 42
Mersana Therapeutics Amends its Licensing Agreement with Adimab 43
Adimab Enters Into Licensing Agreement With Novo Nordisk 44
Biogen Idec Enters Into Licensing Agreement With Adimab 45
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 47
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 48
Adimab LLC – Key Competitors 49
Adimab LLC – Key Employees 50
Adimab LLC – Locations And Subsidiaries 51
Head Office 51
Recent Developments 52
Product News 52
04/25/2016: Adimab Expands Bispecific Antibody Offering with Novel CD3 Program 52
Feb 18, 2016: Adimab Scientists Report the Isolation of Highly Potent Anti-Ebola Virus Antibodies from Recent Zaire Outbreak 53
Other Significant Developments 54
Jan 10, 2017: Adimab Provides Annual Update on 2016 Partnerships and Milestones 54
Apr 25, 2016: Adimab Expands Bispecific Antibody Offering with Novel CD3 Program 55
Jan 11, 2016: Adimab Provides Update on Recent Partnerships and Milestones 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Adimab LLC, Pharmaceuticals & Healthcare, Key Facts 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Adimab LLC, Deals By Therapy Area, 2011 to YTD 2017 10
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Adimab Raises US$13.8 Million In Series F Financing 13
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16
iTeos Therapeutics Enters into Agreement with Adimab 17
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18
Adimab Enters into Research Agreement with Kite Pharma 19
Adimab Enters into Discovery Agreement with Celgene 20
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21
Adimab Enters into Agreement with Acceleron Pharma 22
Adimab Enters into Agreement with Oncothyreon 23
Adimab Enters into Agreement with Surface Oncology 24
Adimab Enters into Agreement with Potenza Therapeutics 25
Five Prime Therapeutics Enters Into Research Agreement With Adimab 26
Jounce Therapeutics Enters Into Research Agreement With Adimab 27
Alector Enters Into Research Agreement With Adimab 28
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29
Adimab Expands Agreement with Innovent Biologics 30
GlaxoSmithKline Expands its Partnership with Adimab 31
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33
Adimab Enters Into Co-Development Agreement With Gilead Sciences 34
Adimab Enters Into Co-Development Agreement With Biogen Idec 35
Adimab Enters Into Co-Development Agreement With Novo Nordisk 36
Arsanis Enters into Agreement with Adimab 37
Eli Lilly Enters into Licensing Agreement with Adimab 38
Arsanis Enters into Licensing Agreement with Adimab 39
Kite Pharma Exercises Option for Licensing Agreement with Adimab 40
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 41
Adimab Enters into Licensing Agreement with Merck 42
Mersana Therapeutics Amends its Licensing Agreement with Adimab 43
Adimab Enters Into Licensing Agreement With Novo Nordisk 44
Biogen Idec Enters Into Licensing Agreement With Adimab 45
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 47
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 48
Adimab LLC, Key Competitors 49
Adimab LLC, Key Employees 50

★海外企業調査レポート[Adimab LLC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HandR Block, Inc.:企業の戦略・SWOT・財務分析
    SummaryHandR Block, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findi …
  • El Pollo Loco Holdings, Inc.:企業の戦略・SWOT・財務分析
    SummaryEl Pollo Loco Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company …
  • Terilogy Co., Ltd. (3356):企業財務及び戦略的SWOT分析
    Summary Terilogy Co., Ltd. (Terilogy) is a technology solution provider that offers software solution to telecommunication and ISPs. The company’s products include apcon intelligent patch panel, radware alteon application switch, netScout packet flow switch, IP appliance, virtualization root cause, …
  • BroadSoft Inc.:企業のM&A・事業提携・投資動向
    BroadSoft Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BroadSoft Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • First Banks, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' First Banks, Inc. Mergers and A …
  • Baltimore Gas and Electric Company (BGLEP):企業のM&A・提携動向(エネルギー分野)
    Summary Baltimore Gas and Electric Company (BGE) is a power transmission and distribution company. It distributes electricity and gas in Baltimore City. The company operates as a subsidiary of Constellation Energy, an integrated energy company in the US. It provides electric services to approximatel …
  • Key Tronic Corporation (KTCC):企業概要、財務及び戦略的SWOT分析
    Summary Key Tronic Corporation (Key Tronic) is a technology and communication service provider. The company offers electronic manufacturing services and solutions. Its products include printers, barcode scanners, standard keyboards, biometric key boards, smartcard key boards, scanning device, digita …
  • SynCore Biotechnology Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary SynCore Biotechnology Co Ltd (SynCore), a subsidiary of Sinphar Pharmaceutical Co Ltd is a biopharmaceutial company that new drug by research and development management and integration of technology resources. The company’s pipeline products include SB01, SB02, SB03, SB04 and SB05; and diagn …
  • Cox and Kings Limited:企業の戦略・SWOT・財務分析
    SummaryCox and Kings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key F …
  • Sany Group Co Ltd:企業の戦略・SWOT・財務情報
    Sany Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sany Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Alliance Data Systems Corporation:企業のM&A・提携・投資分析
    Alliance Data Systems Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Alliance Data Systems Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • MaRS Innovation:医療機器:M&Aディール及び事業提携情報
    Summary MaRS Innovation (MaRS) is a not for profit organization that offers advisory services. The organization’s services include intellectual property, strategy development, business development, operational, marketing resources, project management, financial management, human resources, and inves …
  • J and J Snack Foods Corp:企業の戦略・SWOT・財務分析
    SummaryJ and J Snack Foods Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Ke …
  • China Power New Energy Development Company Limited (735):企業のM&A・提携動向(発電分野)
    Summary China Power New Energy Development Company Limited (CPNEC) is a renewable energy company that provides various clean energy services. The company offers services such as development, construction, owning, operating and management of clean energy power plants. It also provides development of …
  • China Railway Group Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' China Railway Group Limited Mer …
  • OncoSil Medical Limited (formerly NeuroDiscovery, Ltd.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' OncoSil Medical Limited (former …
  • Genesis Energy, L.P.:企業のM&A・提携・投資分析
    Genesis Energy, L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Genesis Energy, L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Nahar Capital & Financial Services Ltd. (NAHARCAP):企業財務及び戦略的SWOT分析
    Summary Nahar Capital & Financial Services Ltd. (NCFSL) is a non-banking finance company that provides investment and financial services. The company’s business activities comprise invests in shares, debentures, stock, bonds and securities, banks, mutual funds and any authority. It also invests in p …
  • Gelsenwasser AG (WWG):企業財務及び戦略的SWOT分析
    Summary Gelsenwasser AG (Gelsenwasser) is a utility consulting company that supplies natural gas and fresh water. The company distributes electricity, gas, water and heat for its residents. It provides online service centers, energy performance certifications, repair services, installing and providi …
  • Darling Ingredients Inc. (DAR):企業概要、財務及び戦略的SWOT分析
    Summary Darling Ingredients Inc. (Darling Ingredients), formerly Darling International Inc is a waste products recycling solutions provider. The company provides a growth platform for the development and production of natural ingredients from edible and inedible bio-nutrients. Its products include r …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆